Annual Report2023
Our mission drives us – More life for people with cancer.
That’s why our work doesn’t stop when the research is done, or the discovery made. The burden of cancer is vast – on patients, their loved ones, and their healthcare providers – but so are our aspirations to redefine how cancer is treated.
More hope. More moments. More life.
Letter to Our Shareholders
Read More“In 2023, we demonstrated the potential for pelabresib to shift the myelofibrosis treatment paradigm, as results from our Phase 3 MANIFEST-2 study showed that all four disease hallmarks were improved with the pelabresib combination therapy over standard of care. Now, in 2024, we are pleased that Novartis is committing to our promising future – helping to maximize the commercial potential of pelabresib in myelofibrosis and accelerate development opportunities across our pipeline.”
Jean-Paul Kress, M.D., Chief Executive Officer
Non-Financial
Group Report2023
We are conscious of the responsibility we share for present and future generations and see sustainable action as a prerequisite for long-term business success. We are focused on creating long-term value and weigh our actions in terms of their impact on the environment, society, patients, and employees.
Non-Financial
Group Report2023
We are conscious of the responsibility we share for present and future generations and see sustainable action as a prerequisite for long-term business success. We are focused on creating long-term value and weigh our actions in terms of their impact on the environment, society, patients, and employees.
Downloadable Versions
Fullscreen
Close
Download